Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.60 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007996 | 0.91 | BRD4 (0.64) | BRD4 | |
| SCHEMBL15328761 | 0.76 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL16008171 | 0.74 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328814 | 0.73 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15329043 | 0.71 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328987 | 0.71 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL15328945 | 0.69 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT | |
| SCHEMBL1252496 | 0.67 | TSHR (0.55) | — | |
| SCHEMBL1252495 | 0.67 | TSHR (0.55) | — | |
| SCHEMBL15328867 | 0.65 | BRD4 (1.00) | BRD4BRD2SMARCA2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | claimed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | claimed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885BRD2 5/4885SMARCA2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.